<< Back to News

FDA Approves First-line Combination Rx for Advanced RCC

On May 14, 2019 Pfizer announced that the FDA has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Resources:

Press Release

For prescribing information for BAVENCIO® and INLYTA®: https://www.bavencio.com/hcp